Skip to content

Multicenter Study to Evaluate the Effectiveness and Safety of Flow-Diverting Stents for Distal Intracranial Aneurysms

Multicenter Study to Evaluate the Effectiveness and Safety of Flow-Diverting Stents for Distal Intracranial Aneurysms

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116837
Enrollment
Unknown
Registered
2026-01-15
Start date
2026-01-31
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Distal Intracranial Aneurysms

Interventions

Flow Diverter Stent System:N/A

Sponsors

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age 18 to 80 years, any gender,Subjects who have accepted treatment with flow-diverting for distal intracranial aneurysms; 2.Diagnosed with an intracranial aneurysm by CTA, MRA, or DSA, with the following features: a wide neck (=4mm), or a dome-to-neck ratio <2, saccular, fusiform aneurysms, recurrent saccular aneurysms, and dissecting aneurysms. Locations include: the Circle of Willis and it's distal branches such as the middle cerebral artery (MCA) M1-M3 segments, anterior cerebral artery (ACA) A1-A3 segments, posterior cerebral artery (PCA) P1-P2 segments, etc. (intracranial aneurysms of the Circle of Willis and it's distal vessels). 3.Subject or guardian is able to understand the purpose of study, shows sufficient compliance with the study protocol and provides a signed informed consent form.

Exclusion criteria

Exclusion criteria: 1.Conditions that are not appropriate for stent delivery and deployment judged by investigators (severe stenosis of parent artery, severe tortuosity of parent artery, stent failing to reach the lesion, stent in the target lesion of parent artery, etc.); 2.mRS score >=3; 3.Heart, lung, liver and renal failure or other severe diseases (intracranial tumor, systemic infection, disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment, history of severe psychosis, severe stenosis or occlusion of cerebral feeding artery, etc.); 4.Platelet count 1.5; 5.Major surgery within 30 days before enrollment,or planned to undergo surgery within 360 days after enrollment; 6.Known allergies or contraindications to anesthetics, anticoagulants, and antiplatelet drugs; 7.Pregnant or breastfeeding women; 8.Subject has participated in other clinical trials within 1 month before signing informed consent; 9.Other conditions judged by the investigators as unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Complete occlusion rate of aneurysm 12 months after surgery;

Countries

China

Contacts

Public ContactJianwei Pan

The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

swordman_pan@aliyun.com+86 571 8723 6628

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026